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Abstract

Drugs exert desired and undesired effects based on their binding interactions with protein target(s) and offtarget(s), providing evidence for drug efficacy and toxicity. Pioglitazone and rosiglitazone possess a common
functional core, glitazone, which is considered a privileged scaffold upon which to build a drug selective for a
given target—in this case, PPARγ. Herein, we report a retrospective analysis of two variants of the glitazone
scaffold, pioglitazone and rosiglitazone, in an effort to identify off-target binding events in the rat heart to
explain recently reported cardiovascular risk associated with these drugs. Our results suggest that glitazone has
affinity for dehydrogenases, consistent with known binding preferences for related rhodanine cores. Both drugs
bound ion channels and modulators, with implications in congestive heart failure, arrhythmia, and peripheral
edema. Additional proteins involved in glucose homeostasis, synaptic transduction, and mitochondrial energy
production were detected and potentially contribute to drug efficacy and cardiotoxicity.

Introduction
Type 2 diabetes drugs rosiglitazone and pioglitazone (Figure 1) are currently the only two thiazolidinedionebased drugs on the market in the United States, and both share a common functional glitazone core. Although
the Food and Drug Administration began restricting access to rosiglitazone in the United States in November of
2011 because of increased risk of myocardial infarction, no such restrictions are in place for pioglitazone. An
earlier thiazolidinedione-based drug, troglitazone, was removed from the market because of hepatotoxic
effects,(1) but rosiglitazone and pioglitazone have not exhibited this effect, despite debate.(2, 3) Rosiglitazone
and pioglitazone are stand-alone therapies for type 2 diabetes or for use in combination with metaformin or
glimedpiride. Both drugs are thought to exert their therapeutic effect via binding to peroxisome proliferatoractivated receptor gamma (PPARγ) in adipose tissue,(4-7) leading to increased insulin sensitivity and better
glycemic control. Despite their chemical and mechanistic similarities, there are large cohort studies suggesting
that rosiglitazone causes peripheral edema(8, 9) and congestive heart failure(10-12) to a greater extent than
pioglitazone. On the other hand, there are additional studies suggesting that there is no increased risk of

peripheral edema(13) and adverse cardiovascular events(14, 15) between rosiglitazone in comparison to
pioglitazone.

Figure 1. Comparison of rosiglitazone and pioglitazone structures (A), showing the shared glitazone core
(privileged scaffold) used to construct the affinity column for purification of proteins that bind the glitazone
core. Under basic conditions, epoxide resin was reacted with the phenoxide of glitazone, and production of the
glitazone-derivatized resin was confirmed using IR spectroscopy (data not shown). (B) Proteins were then eluted
with either rosiglitazone or pioglitazone, and elution profiles, analyzed using tandem mass spectrometry, were
compared.
Serious concerns over cardiovascular events were first raised in 2007 as a result of a meta-analysis suggesting
that rosiglitazone led to a 43% higher risk of myocardial infarction and a 64% higher risk of cardiovascular death
when compared to patients receiving alternative type II diabetes treatments, not including
pioglitazone.(10) Shortly after the 2007 meta-analysis was published, it was challenged because of its lack of
heterogeneity, noting the exclusion of studies with zero events in treatment and control groups.(14, 16) A more
recent and larger cohort study of 227 571 Medicare beneficiaries (average age of 74) identified a statistically
significant 0.4% increased risk for stroke and heart failure as well as “all-cause mortality” for patients treated
with rosiglitazone relative to pioglitazone.(11) However, a study in response to the Medicare beneficiaries study
was published showing that there was no statistically significant difference between rosiglitazone and
pioglitazone in “all-cause mortality” when 36 000 patients (average age of 54) were propensity score matched to
control for variables such as age, gender, and previous history of cardiovascular problems.(15) Regardless, one
argument is that rosiglitazone presents relatively higher cardiovascular risks, yet provides no additional
therapeutic benefit, calling its utility of treating type 2 diabetes patients into question, while pioglitazone has
not yet been reported to tip the benefit/risk balance. Questions as to how and if rosiglitazone may be leading to
a relatively higher cardiovascular risk still remain largely unanswered. This discrepancy as to whether or not
patients taking rosiglitazone run a higher risk of cardiovascular events and death than those taking pioglitazone
and the underlying cause of the cardiovascular risks led to our exploration of the off-target binding profiles.
In a previous study,(17) a chemical proteomic approach was presented for assessing target and anti-target (i.e.,
off-target) protein binding profiles for a rhodanine drug core. A similar approach is used herein to assess
similarities and differences in the heart protein binding profiles between rosiglitazone and pioglitazone
(Figure 1) but with more sophisticated selection techniques and computational/statistical analysis of binding
profiles. As before, the common core or “privileged scaffold” (in this case glitazone) was used to create an
affinity column (Figure 1) to which proteins from the target organ were bound. Rat heart tissue homogenate was
used, since the goal was to identify protein binding events that may be associated with direct cardiovascular

risk. Proteins were eluted with the glitazone-based drugs rosiglitazone or pioglitazone, and eluted proteins were
identified using tandem mass spectrometry (MS). Similarities in binding patterns between these two elutions
may suggest unknown mechanisms of action in addition to PPARγ binding, and possible sources of shared
adverse effects. Conversely, differences may reveal direct protein complex binding events leading to the
increased cardiovascular risk that may be unique to one drug or the other.
In the current study, we have used this modified highly specific technique to make an unbiased comparison of
similarities and differences between off-target molecular mechanisms that could lead to cardiotoxicity for the
two major glitazone-based drugs rosiglitazone and pioglitazone. We used a two-phase selection method in
which the protein must first bind to the privileged scaffold (i.e., glitazone) on the resin and then have higher
affinity for the elution compound (i.e., rosiglitazone or pioglitazone). While our original hypothesis was that
there would be significant off-target protein binding profile differences, thereby explaining an increase in
rosiglitazone cardiotoxicity versus pioglitazone, as suggested by some meta-analyses,(10, 11) the data suggest
that is not the case. Our results suggest that, while there is some differential protein binding, the off-target
binding profiles are quite similar and the majority of proteins with potential for cardiotoxic effects did not
exhibit significant differential binding in comparisons of the drugs, supporting conflicting meta-analyses stating
that they contain a similar cardiotoxic risk.(15, 16) Binding profiles obtained for these drugs suggest that the
cardiotoxic effects could be a result of disruption in ion channel modulation (for example, L-type calcium
channel), neuronal signaling network in the heart, or heart energy demand regulation in diabetic patients taking
both rosiglitazone and pioglitazone. This may implicate the drugs in similar mechanisms of action for adverse
effect reactions due to off-target binding. In addition to PPARγ binding as a mechanism of action, additional
sources of drug efficacy may occur from off-target binding, leading to increased insulin sensitivity. Notably,
there are numerous proteins detected in rosiglitazone and pioglitazone elutions that regulate mitochondrial
function, gluconeogenesis/glycolysis, and lipid metabolism.

Results
Assessing Specificity of Privilaged Scaffold Using Affinity Chromatography
Glitazone was coupled to an epoxy resin to enable privileged scaffold-based (Figure 1) purification of target
organ or tissue homogenate protein binding partners. The TZDs (thiazolidinediones) contained within the core
glitazone scaffold contain the majority of binding interactions seen in crystal structures with PPARγ(4) and have
affinity for the target, so while there is a distinct chance some proteins might be missed, the majority of
interacting proteins and potential complex partners will be captured by the affinity resin. Differences seen in
comparisons of rosiglitazone and pioglitazone elutions will identify proteins with selectivity for these additional
drug functional components, added to the glitazone core. Reaction of the glitazone with an epoxy resin was
confirmed through detection of new hydroxy peaks (−OH) in an infrared (IR) spectrum of the coupled resin (data
not shown), due to opening of the epoxide ring (Figure 1). The IR spectrum indicated that glitazone was
efficiently coupled; an additional phenol column was created using p-cresol and the epoxy resin (data not
shown) for comparison.
Previous literature indicated that a rhodanine group, related to the TZD core of glitazone, exhibits high affinity
for dehydrogenase enzymes in general,(17) so it was utilized as a test group to examine drug specificity for heart
homogenate proteins. Glitazone, rosiglitazone, and pioglitazone elutions all bound numerous dehydrogenase
enzymes. Off of a glitazone scaffold, glitazone eluted 16 dehydrogenase enzymes, rosiglitazone eluted 6, and
pioglitazone eluted 5 (Table 1), showing a higher degree of specificity obtained by the drugs compared to the
core group. Suppression of dehydrogenases have also been shown to effect adipogenesis,(18, 19) a primary
effect of the drugs. Eluted proteins with higher affinity for the drugs will have an increase in peptide/scan count
compared to glitazone or vice versa when normalized for total scan count, helping determine which proteins

demonstrate the highest affinity for the drugs. Additionally, proteins previously shown to be affected in
processing and secretion after administration of TZDs, such as cytoplasmic superoxide dismutase (SODC)
(Supporting Information Table 1), catalase (Suppprting Information Table 2), and numerous ion channels
(Table 4), were found to interact with the drugs, in turn relating specificity further to previous literature.(18, 2026)
Table 1. Dehydrogenase Enzymes with Affinity for the Thiazolidinedione in the Glitazone Scaffold
accession no
.
P15650

description

acyl-CoA dehydrogenase, long-chain specific,
mitochondrial
P04636
malate dehydrogenase, mitochondrial
P42123
l-lactate dehydrogenase B chain
P10860
glutamate dehydrogenase 1, mitochondrial
P04797
glyceraldehyde 3-phosphate dehydrogenase
Q60597
2-oxoglutarate dehydrogenase E1 component,
mitochondrial
P45953
acyl-CoA dehydrogenase, very-long-chainspecific, mitochondrial
P54071
isocitrate dehydrogenase [NADP],
mitochondrial
P08503
acyl-CoA dehydrogenase, medium-chainspecific, mitochondrial
P14152
malate dehydrogenase, cytoplasmic
O08749
dihydrolipoyl dehydrogenase, mitochondrial
P15651
acyl-CoA dehydrogenase, short-chain-specific,
mitochondrial
P04642
l-lactate dehydrogenase A chain
P26284
pyruvate dehydrogenase E1 component αsubunit, mitochondrial
Q9D2G2
dihydrolipoyllysine-residue succinyltransferase
component of 2-oxoglutarate dehydrogenase
complex, mitochondrial
Q9WVK7
short chain 3-hydroxyacyl-CoA dehydrogenase,
mitochondrial
a
ND = not detected.

peps/scans
glitazone
rosiglitazone

pioglitazone

19/85

4/10

14/72

18/182
16/57
15/28
14/48
14/27

3/11
7/15
ND
4/8
ND

NDa
11/32
ND
6/15
5/9

13/23

ND

ND

11/23

ND

ND

10/18

ND

ND

9/23
8/19
6/9

6/17
9/37
ND

ND
10/69
ND

7/19
6/11

ND
ND

ND
ND

4/12

ND

ND

3/12

ND

ND

Because of the importance of achieving high specificity with this two-phase selection purification process,
protein lists were validated further to show enrichment of lower abundance binding partners, expanding the
dynamic range. This validation was completed by comparing nonspecific high salt elutions versus drug elutions
of heart proteins, such as ion channels, off of the glitazone scaffold. For instance, the L-type calcium channel
(CAC1F; rosiglitazone, p = 2.15 × 10–6; pioglitazone, p = 0.000 72), chloride channel protein 6 (CLCN-6;
rosiglitazone, p = 0.000 15; pioglitazone, p = 3.21 × 10–7), and salt-incucible kinase 2 (SIK2; rosiglitazone, p = 4.68
× 10–11; pioglitazone, p = 3.86 × 10–10) were all significantly increased in drug versus high salt elutions off the
glitazone scaffold. This enhancement of the dynamic range of detection was consistently seen across the data
set. An alternative validation was required for those highly abundant proteins that bound to glitazone and had
high affinity for rosiglitazone or pioglitazone because high salt would elute these proteins in abundance off of
the scaffold. Comparisons can be made between the phenol and glitazone scaffold drug elutions to validate this

data set, since the glitazone should contain higher specificity for the proteins than general hydrophobic binding
achieved on the phenol column. By use of ATP synthase β-chain as an example of the more abundant proteins
present, there was significant enrichment by rosiglitazone (p = 0.031) and pioglitazone (p = 0.000 53) off the
glitazone versus phenol scaffolds.

Total Heart Protein Eluted off Glitazone and Phenol Columns
Heart protein homogenates were bound to the glitazone column and eluted off using high salt Tris-buffered
saline, pH 6.8 (nonspecific), 2 mM glitazone (same as scaffold), 50 μM rosiglitazone (selecting for highly specific
binding), and 50 μM pioglitazone (selecting for highly specific binding) elutions. Eluted proteins were prepared
for orbitrap tandem MS analysis and compared against the UniprotKB rodent database. During data analysis
utilizing in-house Visualize software,(27) technical and biological replicates were combined and filtered for
removal of common contaminants and redundant protein/peptide hits, a P ≥ 0.85 for the protein, and a scan
count ≥8 for any given protein. Total protein elution sets consisted of proteins detected from all elution
conditions combined for any given column and filtered as noted above, providing a more complete list of all
proteins bound. In assessing total elution sets (i.e., all elution sets combined and filtered) for both the phenol
(Figure 2A) and glitazone (Figure 2B) columns, there were 349 and 222 total heart proteins, respectively. Of the
total protein elution data set, rosiglitazone displayed a significant increase in 65 proteins (5 unique) eluted off
the glitazone column and 18 proteins (5 unique) eluted off the phenol column compared to the total.
Pioglitazone displayed a significant increase in 37 proteins (1 unique) eluted off the glitazone column and 23
proteins (7 unique) eluted off the phenol column. Only six proteins overlapped between those significantly
increased with rosiglitazone on the two columns and three proteins for pioglitazone elutions, which displayed
the increased specificity of the drugs for elution of proteins bound to the glitazone column. When overlapping
proteins between different elution conditions in the total protein bound data set were accounted for, there
were 156 proteins bound to the glitazone column and 122 proteins bound to the phenol column not significantly
increased when compared to individual drug elution conditions against the total.

Figure 2. Distribution of heart proteins eluted off a phenol or glitazone scaffold, which showed a significant
increase (Sig. ↑; p ≤ 0.05) in abundance relative to total proteins eluted by all conditions (i.e., all detected
proteins bound to the particular column). Elution conditions were compared in terms of the total number of
proteins bound and then eluted from the affinity column. Total protein bound then eluted from the column is
defined as proteins detected by tandem MS for all elution conditions combined and filtered. Numbers of
proteins that showed a significant increase in levels after elutions using high salt TBS (nonspecific) (HS), glitazone
(Glit), rosiglitazone (Rosi), and pioglitazone (Pio) off of the (A) phenol scaffold and (B) glitazone scaffold are
indicated.
Total protein bound comparisons included the most nonspecific elution condition, high salt TBS at pH 6.8, in
which eluted proteins were dependent on a single selection for binding to the core compound (i.e., glitazone).
However, glitazone containing compound elutions contain a second target specific selection process through
addition of the compound in the elution. Comparing the nonspecific single selection with the double selection
protein data sets can skew the numbers, so additional comparisons were generated (Figure 3). In order to focus
on scaffold-bound proteins with the highest degree of specificity for the glitazone compounds, the strategy was
enhanced by focusing on protein data sets compiled by adding a target specific elution by glitazone,
rosiglitazone, and pioglitazone. A three-way comparison of the glitazone containing compound elution protein
data sets (filtered as described for the total protein data sets) was generated (Figure 3). The phenol column
resulted in 101 proteins and the glitazone column in 153 proteins eluting and passing the stringent filters. This
type of analysis is unique because of the two-phase selection of affinity for the compound on the resin and then
a second selection for the compound used for elution. Once again, the specificity among TZD compounds off a
glitazone column compared to the phenol column can be observed by the increase in bound proteins eluted off
by the specific drugs during the specific two-phase selection.

Figure 3. Three-way comparison of proteins found in glitazone, rosiglitazone, and pioglitazone heart protein
elutions off of affinity columns comprised of a phenol or glitazone scaffold. Each sphere represents a specific
elution condition as indicated, and any overlap between spheres is proteins common to multiple conditions. (A)
Comparisons of glitazone, rosiglitazone, and pioglitazone elutions from a phenol scaffold and (B) from a
glitazone scaffold are indicated.

Direct Comparison of Rosiglitazone versus Pioglitazone Elutions off a Glitazone Scaffold
Proteins bound to the glitazone scaffold and eluted with the target-specific glitazone drug contain the highest
degree of specificity and were the focus henceforth. During comparison analysis of rosiglitazone and
pioglitazone elutions, proteins were filtered as before, along with addition of a run count of ≥6, and
normalization for total scan count between groups provided an expected scan count.(27) Comparisons were
then separated into five main categories: (1) unique to rosiglitazone elutions, (2) unique to pioglitazone elutions,
(3) significantly increased in rosiglitazone elutions, (4) significantly increase in pioglitazone elutions, and (5) not
significantly different between the drugs. In direct comparisons of the proteins eluted off the glitazone scaffold
by rosiglitazone or pioglitazone, there were more similarities than differences. Many of the proteins that were
significantly increased with rosiglitazone or pioglitzone in comparisons were still abundant in the elutions
resulting from both drugs. Altogether, 92 heart proteins passed the appropriate filters for the comparison of
rosiglitazone to pioglitazone (Supporting Information Table 1). Of the 92 proteins present in the direct protein
binding comparison data set between rosiglitazone and pioglitazone, 67% (62 proteins) were not significantly

different. Only 6.5% (6 proteins) were unique to rosiglitazone and 6.5% (6 proteins) unique to pioglitazone
(Table 2). There were 11% (10 proteins) and 8.7% (8 proteins) significantly increased in rosiglitazone and
pioglitazone elutions, respectively (Table 3). Since there were few unique differences between rosiglitazone and
pioglitazone, we further assessed the data set by examining those heart proteins that were significantly
increased in abundance (p ≤ 0.05) in elutions by one drug versus the other because those proteins are
candidates to explain mechanistic differences that could result in impaired cardiac function. While rosiglitazone
elutions contained 10 proteins that were significantly increased compared to pioglitazone, the fold change was
much less drastic than the 8 proteins significantly increased by pioglitazone elution (Table 3). The proteins in
Tables 2 and 3 only indicate slight differences in rosiglitazone versus pioglitazone elutions, and the proteins fall
in similar mechanistic pathways compared to those not significantly different between the drugs, indicating they
are potentially affecting the same biological processes. Altogether, both drugs contained off-target binding
partners involved in ion transport modulation (Table 4) and neuronal networks (Table 5), which could have
potential impact on heart muscle contraction. Additionally, proteins involved in the gluconeogenesis/glycolysis
cycle, long-chain fatty acid uptake, transport between the mitochondria and cytoplasm, amino acid metabolism,
and energy transduction were identified (Tables 1–5 and Supporting Information Table 1).

Table 2. Heart Proteins Unique to Rosiglitazone or Pioglitazone Elution off a Glitazone Scaffold
accession no.
Heart-Unique to Rosiglitazone
P48744
P37285
O08755
P14152
Q9WVE8
Q03147
Heart-Unique to Pioglitazone
P16617
P00507
P43432
Q923 × 8
P07335
P20059

annotated protein

scan count
peptides actual
expected norm p

norrin precursor
kinesin light chain 1
hepatocyte nuclear factor 6
malate dehydrogenase, cytoplasmic
protein kinase C and casein kinase substrate in neurons protein 2
cell division protein kinase 7

1
1
1
6
1
1

52
28
18
17
14
9

26.34
14.18
9.12
8.61
7.09
4.56

4.05 × 10–17
6.73 × 10–10
7.47 × 10–7
1.51 × 10–6
1.27 × 10–5
0.00047

phosphoglycerate kinase 1
aspartate aminotransferase, mitochondrial precursor
interleukin-12 β chain precursor
trace amine-associated receptor 7b
creatine kinase B-type
hemopexin precursor

10
6
1
1
5
3

22
20
14
13
11
9

10.86
9.87
6.91
6.42
5.43
4.44

2.49 × 10–8
1.07 × 10–7
8.72 × 10–6
1.83 × 10–5
8.10 × 10–5
0.00036

Table 3. Heart Proteins Present at Relatively Higher Levels after Elution from the Glitazone Scaffold-Based Column Using Rosiglitazone or Pioglitazone
accession no.

annotated protein

Increased with Rosiglitazone vs
Pioglitazone Elution
P09321
chorionic somatomammotropin hormone 2
precursor
Q8BQP8
Rab11 family interacting protein 4
Q9QX72
SECIS-binding protein 2
Q04690
neurofibromin
Q8BGE5
Fanconi anemia group M protein homologue
Q4FZZ1
PX domain-containing protein kinase-like
protein
Q9QZM3
cardiotrophin-like cytokine factor 1 precursor
Q9QUH6
Ras GTPase-activating protein SynGAP

peptides

scan count
rosi/exp

pio/exp

fold
change

norm p

1

12/7.60

3/7.40

3.92

0.018

2
1
3
3
1

15/9.62
44/29.37
12/8.10
17/11.65
23/16.21

4/9.38
14/28.63
4/7.90
6/11.35
9/15.79

3.74
3.22
3.10
2.94
2.64

0.011
8.12 × 10–5
0.046
0.023
0.014

1
2

25/17.73
62/46.09

10/17.27
29/44.91

2.56
2.12

0.012
0.00073

Q9QZR6
Q9QXY7
Increased with Pioglitazone vs
Rosiglitazone
P48500

septin-9
membrane transport protein XK

1
1

59/44.06
61/46.59

28/42.94
31/45.41

2.08
1.88

0.0012
0.0024

triosephosphate isomerase

13

6/30.89

55/30.11

6.46

8.61 × 10–
12

P00564
P15650
Q9CZU6
P83741
P42123
O08749
P16951

creatine kinase M-type
acyl-CoA dehydrogenase, long-chain-specific,
mitochondrial precursor
citrate synthase, mitochondrial precursor
serine/threonine-protein kinase WNK1
l-lactate dehydrogenase B chain
dihydrolipoyl dehydrogenase, mitochondrial
precursor
cyclic AMP-dependent transcription factor
ATF-2

12
14

4/18.74
10/41.53

33/18.26
72/40.47

6.16
5.78

2.38 × 10–7
1.59 × 10–
13

10
3
12
10

5/19.25
4/8.10
15/23.80
37/53.68

33/18.75
12/7.90
32/23.20
69/52.32

5.52
3.24
2.26
1.88

1.06 × 10–6
0.036
0.0094
0.0011

1

18/24.82

31/24.18

1.64

0.050

Table 4. Ion and Small Molecule Channels plus Modulators Eluted by Both Rosiglitazone and Pioglitazone from the Glitazone Scaffold-Based Columna
scan count
accession no. annotated protein
peptides rosi/exp
pio/exp
P10719
ATP synthase β chain, mitochondrial
10
34/32.4
30/31.6
P15999
ATP synthase α chain, mitochondrial
18
70/62.8
54/61.2
O35454
chloride channel protein 6
1
9/12.7
16/12.3
P20059
hemopexin
3
0/4.6
9/4.4
P70600
focal adhesion kinase 2
1
6/5.6
5/5.4
Q9QXY7
membrane transport protein XK
1
61/46.6
31/45.4
Q4FZZ1
PX domain-containing protein kinase-like protein (modulator of Na,K-ATPase) 1
23/16.2
9/15.8
P83741
serine/threonine-protein kinase WNK1
3
4/8.1
12/7.9
O70247
sodium-dependent multivitamin transporter
1
4/5.6
7/5.4
Q5QD11
trace amine-associated receptor 7b
1
0/6.6
13/6.4
Q9JIS7
voltage-dependent L-type calcium channel, α-1F subunit
3
14/10.6
7/10.4
a
∗ denotes significant p-value for an increase with rosiglitazone and # denotes significant p-value for increase with pioglitazone.

norm p
0.69
0.2
0.14
3.6 × 10–4#
0.8
0.0024*
0.014*
0.036#
0.34
1.83 × 10–5#
0.14

Table 5. Heart Proteins Eluted from the Glitazone Scaffold-Based Column Using Rosiglitazone and Pioglitazone That Are Implicated in Neuronal
Synaptic Transmission or Developmenta

scan count
accession no. annotated protein
peptides rosi/exp
pio/exp norm p
Q8CGZ2
afadin- and α-actinin-binding protein
1
12/11.6
11/11.4 0.88
Q91ZU6
bullous pemphigoid antigen 1 (dystonin)
12
9/7.6
6/7.4
0.47
Q9QZM3
cardiotrophin-like cytokine factor 1
1
25/17.7
10/17.3 0.0.012*
O08788
dynactin-1
3
13/11.1
9/10.9
0.43
P97924
Huntingtin-associated protein-interacting protein (kalirin)
3
27/30.4
33/29.6 0.38
Q9EPL8
importin-7
1
15/13.2
11/12.8 0.47
Q04859
serine/threonine-protein kinase MAK
1
16/16.2
16/15.8 0.94
Q8VBX6
multiple PDZ domain protein
2
9/10.1
11/9.9
0.61
P48744
norrin
1
52/26.3
0/25.7
4.05 ×10–17*
Q04690
neurofibromin
3
12/8.1
4/7.9
0.046*
Q9JLB5
neuronal acetylcholine receptor protein, α-10 subunit
1
7/6.1
5/5.9
0.59
Q9WVE8
protein kinase C and casein kinase substrate in neurons protein 2 1
14/7.1
0/6.9
1.27 × 10–5*
O88761
26S proteasome non-ATPase regulatory subunit 1
3
15/13.7
12/13.3 0.61
Q9Z139
tyrosine-protein kinase transmembrane receptor ROR1
1
5/6.5
8/6.4
0.38
P35710
transcription factor SOX-5
1
11/8.6
6/8.4
0.24
Q9QUH6
Ras GTPase-activating protein SynGAP
2
62/46.1
29/44.9 7.32 × 10–4*
a
∗ denotes significant p-value for an increase with rosiglitazone, and # denotes significant p-value for increase with pioglitazone.

Heart Off-Target Protein Binding Profile Trends for Rosiglitazone and Pioglitazone
Elutions
Since most of the off-target binding partners for both rosiglitazone and pioglitazone are similar, further analysis
of the 92 protein comparison data set focused on exploring directly affected pathways or classes of proteins
shared between rosiglitazone and pioglitazone elutions. There were 10 ion channels or channel regulators
detected at a similar abundance for rosiglitazone and pioglitazone, including regulators of small amine, calcium,
chloride, sodium, and electron transport (Table 4). Identified were a voltage-dependent L-type calcium channel,
a calcium channel regulator FAK2, mitochondrial adenosine triphosphatases (ATPases), and various modulators
of sodium and chloride transport. L-Type calcium channels have a central role in cardiac function, including
effects on cardian arrhythmias. Only the membrane transport protein XK (p = 0.0024) and modulator of Na,KATPase (p = 0.014) were significantly increased in rosiglitazone elutions and trace amine-associated receptor 7b
(p = 1.83 × 10–5), WNK1 (p = 0.036), and hemopexin (p = 3.6 × 10–4) in pioglitazone elutions. Interestingly,
numerous modulators of amine transport are linked to not only cardiovascular function but also
neurotransmitter regulation and excitable synaptic transmission.
Numerous proteins within the rosiglitazone and pioglitazone comparison were also implicated in neuronal
function and excitatory synaptic transmission. Not including the channels mentioned above, there were 16
proteins in the rosiglitazone and pioglitazone comparison that mediate neuronal functions (Table 5).
Cardiotropin-like cytokine factor 1 (p = 0.012), nerofibromin (p = 0.046), and Ras GTPase-activating SynGAP (p =
7.32 × 10–4) were significantly increased in rosiglitazone elutions, and norrin (p = 4.05 × 10–17) plus PACSN2 (p =
1.27 × 10–5) were unique. The other 11 proteins implicated in synaptic transmission were not significantly
different between the drugs. To determine if the ion channels, channel modulators, and synaptic transmission
regulators were in unique networks to the heart and not a general network of proteins throughout the body, we
compared the heart elution profiles of rosiglitazone and pioglitazone to liver off-target binding profiles (data not
shown) generated in the same manner as with the heart (Tables 4 and 5). Proteins identified in
Tables 4 and 5 were found to be unique or significantly increased in the heart elution data set versus the liver,
suggesting that the drugs bind a unique set of ion/amine channels and neuronal excitatory network in the heart.
Rosiglitazone and pioglitazone have been shown to bind purified PPARγ with high affinity in purified samples
and have been indirectly shown to activate the PPARγ pathway;(4, 6, 7) target organs in vivo are adipose and
liver. However, it is unclear if this direct PPARγ interaction would occur in the rat heart. In the exploration of the
tandem MS data sets from rosiglitazone and pioglitazone heart protein elutions off of the glitazone scaffold,
there was no PPARγ detection. To assess whether the expression was too low in the heart for detection, the
glitazone column elution experiments were repeated by substituting fatty rat liver tissue homogenates in place
of those generated from the heart. PPARγ was detected minimally in rosiglitazone elutions (1 peptide/4 scans)
but not in pioglitazone elutions off the glitazone column. On the other hand, PPARδ was detected in both
rosiglitazone (1 peptide/3 scans) and pioglitazone (1 peptide/10 scans) elutions of liver protein off the glitazone
column. The heart, liver, and adipose samples were further examined by PPARγ immunoblotting showing low
expression in the heart (data not shown). The low expression of PPARγ in the heart sample also fits with known
mRNA expression profiles for the protein in various mammalian species.(28-30) Given the low expression levels
of transcription factors, it is expected that PPARγ detection would be challenging via MS even if present in
elutions because of the presence of the more abundant proteins and dynamic range limitations by mass
spectrometry. Among proteins detected in rosiglitazone and pioglitazone elutions off of the glitazone column,
there were 22 involved in fatty acid metabolism, tricarboxylic acid metabolism, glycolysis/gluconeogenesis, and
insulin signaling pathway regulation (Supporting Information Table 1). Within these processes mitochondrial
respiration, the citric acid (TCA) cycle and energy regulation were implicated. The salt-inducible kinase 2 (SIK2)
protein that phosphorylates the insulin receptor substrate 1 (IRS-1) protein at Ser794 and subsequently causes

insulin resistance(31, 32) was also found on this list of proteins and was one of only two proteins significantly
increased in binding versus total protein (Figure 2 and Supporting Information Table 1) in both rosiglitazone and
pioglitazone elutions.

Discussion and Conclusions
The two main goals of this study were first to develop a unique two-phase selection technique for assessing
pharmaceutical off-target protein binding and, second, to compare similarities and differences between the offtarget protein binding profiles for rosiglitazone and pioglitazone, providing clues for assessing cardiotoxicity. To
achieve these goals, proteins from rat heart homogenates were selected for interaction with a glitazone
privileged scaffold and eluted using high salt, glitazone, rosiglitazone, or pioglitazone, followed by subsequent
identification via LC–MS/MS analysis. By use of sophisticated computational analysis of identified
proteins,(27) several findings emerged that provide insights into rosiglitazone and pioglitazone mechanistic
action within the cardiovascular system, including implications for compounding drug efficacy and cardiotoxicity.
First, most of the heart proteins identified eluted with both rosiglitazone and pioglitazone, suggesting that they
have a similar mechanistic action and similar potential for producing cardiotoxicity. Second, of the protein
binding partners that were common between rosiglitazone and pioglitazone elutions from the glitazone scaffold,
only a small subset were differentially eluted with one drug versus the other (Tables 2 and 3). Third, several
common classes of proteins were identified in rosiglitazone and pioglitazone elutions off a glitazone scaffold
that possess the potential for an increase in drug efficacy or adverse cardiovascular events. Some examples are
ion channels and solute transporters, lipid metabolism proteins, and mitochondrial proteins involved in meeting
the high energy demands of the heart. It is especially significant that ion channels, such as L-type calcium
channels, were identified, as they play a central role in maintaining proper cardiac rhythms. Lastly, PPARγ
elution off the glitazone scaffold was not detected in elutions from cardiac tissue most likely because of low
levels of expression,(28-30) while it was detected in elutions from liver and adipose tissue homogenates. It is
possible that off-target protein binding partners, in addition to PPARγ, could contribute to TZD efficacy,
especially since data on direct binding of TZDs to the receptor in complex mixtures are not well-defined. In this
regard, several other off-target binding partners were identified that indirectly or directly could affect the
degree of insulin sensitivity.
Rosiglitazone and pioglitazone are thought to exert their primary therapeutic effects through binding to the
peroxisome proliferator-activated receptor gamma (PPARγ) in adipose tissue, in turn increasing sensitivity to
insulin and producing better glycemic control.(4-6) It is clear from previous literature that TZDs can bind purified
PPARγ(4, 6, 7) and either directly or indirectly cause activation of the PPARγ pathway signaling as measured by
activity assays.(5, 33) The established targets of rosiglitazone and pioglitazone, PPARγ and PPARδ, were
detected sporadically and at low scan counts in the tandem MS analysis of various elution conditions but not at
levels that passed the stringent run count filters. This is not surprising, since PPARγ is expressed at low levels in
the heart,(28-30) which we also verified in our homogenates by immunoblotting (data not shown). However, rat
liver (Supporting Information Table 2) and adipose (data not shown) tissue homogenates did not exhibit high
levels in elutions either, although they were identified as present. This low level of detection could be because
(1) transcription factors are present at low levels, such as with PPARγ in the heart,(28-30) making detection
particularly challenging because of dynamic range limitations from more abundant proteins in the eluent, (2)
PPAR is not binding the column (i.e., glitazone itself is not sufficient for binding or cofactors are required), (3)
glitazone has higher affinity for other proteins in the complex protein homogenate compared to PPARγ, or (4)
PPARγ could be occupied with free lipid byproducts from the homogenization step preventing drug binding. Free
LDL levels have been shown to increase in rat serum after administration of rosiglitazone,(20) which could also
lead to increased PPARγ pathway activation. However, questions as to whether additional drug efficacy is

achieved through receptor-independent off-target actions of TZDs remain, since it is possible that some drug
efficacy could be attributed to binding to proteins in addition to PPARγ.(18, 34)
Receptor-independent actions of rosiglitazone and pioglitazone have been reported in previous literature,(18,
34) and this study has identified numerous off-target interacting proteins involved in mitochondrial function,
lipid/fatty acid metabolism, and glycolysis/gluconeogenesis regulation (Tables 1–4 and Supporting Information
Table 1). Previous literature has indicated that PPARγ antagonists and transcriptional/translational inhibitors do
not abolish TZD effects,(18, 35) suggesting that there are additional effects contributing to increasing insulin
sensitivity. A potential nonreceptor candidate protein that has potential to directly affect insulin receptor
sensitivity, SIK2, was detected in this study for both TZDs tested (Supporting Information Table 1). SIK2 is known
to phosphorylate IRS-1 Ser794, rendering it inactive during nutrition deprivation, causing insulin resistance.(31,
32) A potential alternative hypothesis for increased insulin sensitivity with application of rosiglitazone and
pioglitazone could be that SIK2 binds to the drugs and IRS-1 Ser794 phosphorylation in adipocytes is inhibited,
thus increasing insulin sensitivity. Additional receptor-independent off-target binding partners for the TZDs
(Tables 1–5 and Supporting Information Table 1), as indicated in this study, are involved in altering
mitochondrial aerobic respiration, which in turn leads to changes in metabolism, energy production, and
consequently insulin sensitivity (Figure 4).(18, 36-38) Pyruvate dehydrogenase, malate dehydrogenase, isocitrate
dehydrogenase, acetyl-CoA dehydrogenases, and citrate synthase are all part of the citric acid cycle proximal to
complex I in the mitochondria and were detected to be individual or complex binding partners for TZDs.
Previous studies suggest that TZD inhibition of complex I or proximal to the complex affect mitochondrial
respiration and cause alterations in energy states, in turn increasing insulin-sensitizing effects.(18, 3638) Additionally, dehydrogenase enzymes have been shown to exhibit direct involvement in adipogenesis.(19)
While there were slight differences in the off-target binding profiles between rosiglitazone and pioglitazone,
there were many more similarities in individual protein and pathway comparisons, suggesting that the drugs
may operate through similar off-target mechanisms in terms of both efficacy and potential toxicity. Resulting
off-target binding profiles of both rosiglitazone and pioglitazone show that the drugs bind to mitochondrial
respiratory chain proteins (Tables 1–4), as well as a large number of ion channels and solute transporters
(Table 4) previously implicated in abnormal cardiovascular functions. Energy deprivation produced from
inhibition of mitochondrial respiration has the potential to increase insulin sensitivity(18, 37) but could also lead
to a lack in fulfilling the high energy demands of cardiac tissue (Figure 4). Not only were there TCA cycle proteins
bound to both pioglitazone and rosiglitazone, ATP synthase was also bound, which is crucial for utilizing the
proton gradient from mitochondrial respiration to produce ATP energy for tissues. TZDs have been shown to
cause mitochondrial dysfunction and decrease mitochondrial ATP production.(18, 37, 38) Deficiencies in
mitochondrial ATP synthase can lead to hypertrophic cardiomyopathy.(39, 40) Additionally, pioglitazone bound
to phosphoglycerate kinase 1, triosphosphate isomerase, and creatine kinase at significantly increased amounts
compared with rosiglitazone; all are involved in providing energy for high energy demanding tissues.
TZD inhibition in the mitochondrial machinery can also lead to an increase in reactive oxygen species (ROS)
through complex I inhibition.(41) TZD-induced depolarization of the mitochondria in astroglioma cells has been
shown to increase ROS, which interacts with nitric oxide to form a cytoxic peroxynitrate.(41) Both rosiglitazone
and pioglitazone bound numerous proteins involved in clearance of ROS. SODC and glutathione (GSH) levels
have previously been shown to decrease, while catalase increased, in the serum of Wistar rats after application
of rosiglitazone or pioglitazone.(20) Besides SODC and catalase, bound to both drugs was the selenocysteine
insertion sequence binding protein 2 (SEPB2) (Table 3), which adds the essential trace element selenium to the
reactive site of GSH peroxidase (GPx) and is required for its function. Mutations in SEPB2 exhibit a similar
phenotype to GPx mutants and lead to an increase in ROS production, which coincidently leads to an increase in
insulin sensitivity.(42) While SOD did not appear functionally affected in activity assays following treatment with

both drugs (data not shown), the potential buildup of ROS in relation to alterations in any of these key points of
regulation within the ROS pathway could lead to cardiotoxicity, possibly through an oxidase-independent
mechanism.(41)
In addition to channels like ATP synthase, numerous ion channels or amine transporters were bound to the TZDs
and dysfunction in regulation could affect frequency and force of heart tissue contractions resulting in
arrhythmia, heart attack, or even peripheral edema and congestive heart failure. Proteins detected as “top hits”
for rosiglitazone and pioglitazone elutions included the voltage-dependent L-type calcium channel (CAC1F),
chloride channel protein 6 (CLCN-6), neutral amino acid transporters, and membrane transport protein XK (XK).
Disruption of the L-type calcium channel could be beneficial but certainly affects cardiac rhythym and under
persistent alterations in activity could be a source of cardiotoxicity. Importantly, there have been reports that
TZDs can directly interact with and affect L-type calcium channels,(24-26, 43-45) thereby validating our findings
that suggest drug binding to CAC1F. Numerous other sodium, potassium, chloride, and amine transporters
detected in this study have also been shown to exhibit regulation of action potential and membrane polarization
by various TZDs.(21-23, 25, 46-50) Distinct excitatory synaptic transduction regulating proteins were also
detected and could potentially have similar adverse effects on the heart and cardiovascular system (Table 5) but
via the sympathetic system.
While previous literature clearly suggests that rosiglitazone increases the risk of adverse cardiac-related
events,(10, 11) our data would suggest that pioglitazone is very similar in terms of the rat heart binding profiles.
These profiles identify potential direct sources contributing to both efficacy and cardiotoxicity via perturbations
in mitochondrial function, cardiac ion channels (for example, L-type calcium channels), and disruption of the
cardiac sympathetic signaling. While rosiglitazone and pioglitazone off-target protein binding profiles are very
similar in composition, there is the chance for variance in effects based on affinity for the particular protein
leading to slight differences in efficacy or cytotoxicity.(49, 51-53) Additionally, it is recognized that long-term
dosing of an animal model with rosiglitazone or pioglitazone may lead to increased levels of additional off-target
binding partners and that indirect effects could contribute to efficacy and cardiotoxicity (Figure 4). One must
also keep in mind that patients taking these drugs are also the severe type II diabetic patients for whom other
forms of regulation are not therapeutically effective and their cardiovascular system is already severely impaired
making them high risk, which could also be a contributing factor. There is also literature that suggests that
adverse events could be dependent on age and increasing cardiotoxicity in elderly patients.(11, 15)

Figure 4. Model summarizing rosiglitazone and pioglitazone (1) receptor-independent (off-target) interactions
detected in this study and the (2) receptor-dependent interaction with PPARγ leading to increased insulin
sensitivity. Off-target interactions that potentially increase cardiotoxicity include effects on ion channels leading
to cardiac arrhythmias, altered membrane potential, and congestive heart failure. Additionally, mitochondrial

dysfunction would affect energy regulation in the heart, not only leading to cardiotoxicity but also indirectly
contributing to efficacy of the drugs.
The techniques presented herein, which provide a comparison of binding profiles as chemical structures of drugs
are varied, could also be used to make additional improvements to existing drugs or to find existing drugs with
similar elution profiles. Once proteins associated with potential for adverse effects are identified, the core
scaffold can be systematically modified to tune the binding profile in such a way as to avoid binding to undesired
proteins, as described previously.(17) The latter application suggests utility in repurposing drugs to identify
drugs with desirable off-target binding profiles, if one elutes from a column containing a core from one drug,
using a second drug that is thought to operate by a different mechanism but actually may bind similar proteins.
Experimental approaches such as this are the subject of ongoing studies in our laboratories and provide
invaluable information to decipher both beneficial and cytotoxic interactions of drugs.

Experimental Methods
Coupling of Glitazone to the Epoxy Resin
Epoxide resin (1.5 g) was incubated in phosphate buffer solution (Na2HPO4 and KH2PO4) at pH 10 for 3 h. Then
0.8 g of K2CO3 and 1.9 g of glitazone were added, followed by gentle aggitation for 3 days at room
temperature. p-Cresol, potassium carbonate, potassium phosphate (monobasic), sodium phosphate (dibasic),
and an epoxide functionalized resin (∼2 mmol/g) were from Alfa Aesar, and 5-(4-hydroxybenzyl)-1,3thiazolidine-2,4-dione (glitazone, ≥97% purity as determined by HPLC) was from Accela ChemBio Inc. IR spectra
were collected on a Nicolet 560 FT-IR spectrometer, in a KBr pellet, to confirm coupling. In the same manner, a
control column was prepared by coupling with 1.6 g of p-cresol (Alfa Aesar) in place of glitazone.

Preparation of Rat Heart and Liver Homogenates
Sprague–Dawley rats of 8–10 weeks of age on a 4% NaCl diet were sacrificed using 0.3 mL of Beuthenasia.
Hearts and livers were excised and quartered into 2 mL microcentrifuge tubes followed by liquid nitrogen snap
freezing. Then 5 mm stainless steel beads (Qiagen, catalog no. 69989) were added to each tube for bead
homogenization along with 1 mL of low salt 1× TBS, pH 7.8. A TissueLyser II was used at 20 Hz frequency for 90 s
three times and 30 Hz for 120 s two times to generate crude homogenates for heart and liver samples. Crude
homogenates were centrifuged at 3500g (4600 rpm) for 15 min at 4 °C for removal of high molecular weight
debris. Supernatants were transferred to 2 mL Beckman centrifuge tubes and balanced and underwent
ultracentrifugation for 30 min at 100000g (55 000 rpm) at 4 °C. Supernatants were transferred to a fresh tube,
and microsomal pellets were resuspended in 0.5–1.0 mL of low salt 1× TBS, pH 7.8, depending on the pellet size.
MicroBCA assay (BioRAD) was then performed on the soluble and microsomal protein fractions, while the
remaining protein mixtures were snap frozen and stored at −80 °C for future use.

Eluting Rat Heart Protein Using Glitazone
Both the glitazone and control columns were equilibrated in buffer A (low salt TBS: 25 mM Tris-HCl, 50 mM
NaCl, pH 7.8). Then 0.5 mg of protein sample (either soluble or membrane fraction) was loaded onto the
columns and incubated for 15 min. Then both columns were washed with buffer A (10–15 bed volumes), and
flow-through was saved. Columns were eluted using buffer B (2 mM glitazone in buffer A), and fractions were
collected. Columns were flushed using high salt TBS buffer (1 M NaCl, 10 mM Tris, pH 7.8) and then reequilibrated with 20 bed volumes of buffer A.

Eluting Rat Liver Protein Using Rosiglitazone and Pioglitazone
The glitazone column was equilibrated in low salt TBS (25 mM Tris-HCl, 50 mM NaCl, pH 7.8). Then 0.5 mg of
protein sample (either soluble or membrane fraction) was loaded onto the column and incubated for 15 min.

Then the column was washed with buffer A (10–15 bed volumes), and flow through was saved. Column was
eluted with buffer B (50 or 500 μM rosiglitazone or pioglitazone in buffer A), and fractions were collected.
Columns were flushed using high salt TBS (1 M NaCl, 10 mM Tris), pH 6.8, and re-equilibrated with buffer A. 5[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride (pioglitazone or Actos)
was from Sigma-Aldrich and 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
(rosiglitazone or Avandia) was from Cayman Chemical Company. Both rosiglitazone and pioglitazone were ≥98%
pure as determined by HPLC.

Preparation of Samples for Mass Spectral Analysis
Buffer exchange into 50 mM ammonium bicarbonate was performed using Amicon Ultra-15 Ultracel centrifugal
filters with a 3000 Da molecular weight cutoff (Millipore, Billerica, MA) using four 20 min cycles at 3500g.
Samples were dried using a vacuum centrifuge and resuspended in 100 μL of 50 mM ammonium bicarbonate.
Protein samples were then reduced with 10 mM dithiothreitol at 56 °C for 30 min, cooled to room temperature,
alkylated with 20 mM iodoacetamide for 30 min in the dark, and digested using 0.5 μg of sequencing grade
trypsin (Promega) overnight (∼16 h) at 37 °C. Peptide mixtures were acidified (∼pH 4), and Varian Omix C18
desalting tips (Agilent Technologies, Santa Clara, CA) were used to clean and elute peptides. Desalted peptides
were dried using a vacuum centrifuge and resuspended in 98% HPLC water/2% ACN/0.1% formic acid.

Liquid Chromatography and Mass Spectrometry
Tryptic peptide mixtures (1.9 μL) were injected via a NanoAccuity UPLC system (Waters, Milford, MA) and
passed over an in-house packed C18 resin (Phenomenex, Torrance, CA) column (10 cm long, 50 μm inner
diameter). A gradual gradient from 98% HPLC water/2% ACN/0.1% formic acid to 98% ACN/2% HPLC water/0.1%
formic acid was applied to peptide mixtures. As peptides eluted, they were analyzed using an Orbitrap Velos
mass spectrometer (Thermo Scientific, Waltham, MA). Initial parent ion scans (MS1) were performed in the
FTMS portion with 106 ions collected over a maximum accumulation time of 500 ms and a resolution of 30 000
at full width of a spectral peak at half-maximum peak height (fwhm at 400 m/z). The 10 most abundant ions
were selected for collision induced dissociation fragmentation (MS/MS) in the LTQ ion trap portion of the
instrument with an ion intensity threshold of 500 and a normalized collision energy of 35%. Ten-thousand ions
were collected from fragmentation spectra over a maximum accumulation time of 25 ms. Dynamic exclusion
was used, excluding any given mass observed more than once in a 30 s time frame for 180 s from selection for
fragmentation.
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Abbreviation Used
LTQ
TZD
SOD
SIK2
IRS-1
CLCN-6
CAC1F
SEPB2
GSH
GPx

linear trap quadrupole
thiazolidinedione
superoxide dismutase
salt-inducible kinase 2
insulin receptor substrate 1
chloride channel protein 6
voltage-dependent L-type calcium channel
selenocysteine insertion sequence binding protein 2
glutathione
glutathione peroxidase
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